The Integrated Training in Pharmacological Sciences Program at Mount Sinai aims to provide rigorous multi- disciplinary pre-doctoral research education that fosters the ability of Program graduates to enhance discovery of new drugs. The diverse approaches will include identification of new targets, new screens or structural information to inform drug design, methods for prediction/demonstration of the safety of a drug and its side effects, and methods to predict opportunities for re-purposing drugs that have already been in approved use. The need for scientists with such skills is clear since we face: a paucity of new therapeutics in the pipeline;a lack of effective therapeutic options for too many diseases;a perplexingly wide range of responses among different individuals to a particular drug;and a need for innovative therapeutic options that include drug combinations and new strategies to overcome drug resistance. The Training Program will engage trainees in computational and systems biological applications to the "omics" and other large data set analyses that inform new testable models of disease and reveal potential new therapeutic strategies. These approaches will become the project areas for some trainees, while others pursue structural or chemical approaches to develop information about new targets or to inform the design of new drugs. Some trainees will focus on developing the new computational tools that can be applied to disease- or therapeutic-related network analyses, while others focus on particular biomedical problems. The Training Program fosters the ability of trainees with these diverse specializations to take collaborative advantage of each other's expertise. The proposed group of up to 12 trainees per year will typically receive support from the Training Program for 2-3 years, starting after the first or first two training years for Ph.D. and MD/Ph.D. students, respectively. The Ph.D. degree is typically completed within 5.5 years from matriculation. The highly collaborative group of 42 participating faculty members comes from 11 different departments, both basic science and clinical. It includes 17 faculty members from the Pharmacology and Systems Therapeutics Department and 5 from the Structural and Chemical Biology Department, the major contributing departments to the school-wide Experimental Therapeutics Institute (ETI). ETI provides research groups with access to emerging tools for drug development. Most trainees pursue their Ph.D. coursework in the Systems Biology of Disease and Therapeutics training area of the Graduate School and most participating faculty contribute to the teaching efforts. Graduates of the Program, use their training in a gratifying array of academic and pharmaceutical settings and other paths, in which they apply the special skill sets they bring from their pre-doctoral training.

Public Health Relevance

Breakthroughs that yield new drugs that ameliorate different human diseases, that yield new diagnostics or new therapeutic strategies, depend more and more upon researchers who apply quantitative computational methods to the complex biology of disease and drug interactions. We aim to foster these skills in talented Ph.D. and MD/Ph.D. students, enabling them to achieve the next generation of breakthroughs.

Agency
National Institute of Health (NIH)
Type
Institutional National Research Service Award (T32)
Project #
2T32GM062754-14
Application #
8607816
Study Section
(TWD)
Program Officer
Okita, Richard T
Project Start
Project End
Budget Start
Budget End
Support Year
14
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Pharmacology
Type
Schools of Medicine
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10029
Kim, S H; Steele, J W; Lee, S W et al. (2014) Proneurogenic Group II mGluR antagonist improves learning and reduces anxiety in Alzheimer A? oligomer mouse. Mol Psychiatry 19:1235-42
Steele, John W; Brautigam, Hannah; Short, Jennifer A et al. (2014) Early fear memory defects are associated with altered synaptic plasticity and molecular architecture in the TgCRND8 Alzheimer's disease mouse model. J Comp Neurol 522:2319-35
Bouhaddou, Mehdi; Birtwistle, Marc R (2014) Dimerization-based control of cooperativity. Mol Biosyst 10:1824-32
Bruns, Ingmar; Lucas, Daniel; Pinho, Sandra et al. (2014) Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion. Nat Med 20:1315-20
Smith, Steven G; Sanchez, Roberto; Zhou, Ming-Ming (2014) Privileged diazepine compounds and their emergence as bromodomain inhibitors. Chem Biol 21:573-83
Costa, Justin A; Nguyen, Dac A; Leal-Pinto, Edgar et al. (2013) Wicking: a rapid method for manually inserting ion channels into planar lipid bilayers. PLoS One 8:e60836
Lane, Rachel F; Steele, John W; Cai, Dongming et al. (2013) Protein sorting motifs in the cytoplasmic tail of SorCS1 control generation of Alzheimer's amyloid-? peptide. J Neurosci 33:7099-107
Zhao, Shan; Nishimura, Tomohiro; Chen, Yibang et al. (2013) Systems pharmacology of adverse event mitigation by drug combinations. Sci Transl Med 5:206ra140
Na, Jianbo; Musselman, Laura Palanker; Pendse, Jay et al. (2013) A Drosophila model of high sugar diet-induced cardiomyopathy. PLoS Genet 9:e1003175
Golden, Sam A; Christoffel, Daniel J; Heshmati, Mitra et al. (2013) Epigenetic regulation of RAC1 induces synaptic remodeling in stress disorders and depression. Nat Med 19:337-44

Showing the most recent 10 out of 50 publications